AUTOLOGOUS MORROW TRANSPLANTATION

该计划项目的总体目标是改善以下项目的结果 自体骨髓移植在血液病治疗中的应用 恶性肿瘤。本计划将涉及的一般主题 该项目包括根除恶性肿瘤、克隆性 造血，外周血祖细胞对植入的影响， 生长因子的影响和阻断体内生长抑制物的尝试。 提出了七个单独的研究项目，这些项目将会奏效 就以下主题进行协作： 1.资产负债表的评估。 A.急性淋巴细胞性白血病和恶性淋巴瘤。 B.急性髓系白血病。 2.基因标记的外周血造血细胞对 异基因移植后的造血重建。 3.造血生长因子：临床前评价。 4.集落形成细胞：急性髓系祖细胞的生成 白血病。 5.克隆性造血：对恶性和非霍奇金淋巴瘤克隆起源的评价 造血术。 6.自体骨髓移植中的生长因子。 7.淋巴因子与AMT后过继免疫治疗的评价。 我们开展本计划项目中建议的研究的能力是 加强了：1)以小鼠为重点的临床前研究计划， 犬类或非人类灵长类动物模型，并允许快速和合乎逻辑的翻译 临床前概念到临床试验，2)超过120 每年对自体移植患者进行研究，3) 生物统计学、骨髓处理、门诊的支持性护理计划 和长期随访，病理学，传染病咨询， 药理学、营养服务、输血支持和管理， 和4)独特的结构，作为一大群调查人员，他们都是 聚焦于骨髓移植的一般话题。在以下方面取得成功 实现本计划项目的目标将与使用相关 其他治疗恶性血液病的强化疗法， 羊膜移植在其他恶性肿瘤治疗中的广泛应用 非恶性疾病，以及全血细胞增生性疾病和 免疫功能受损的病人。

The overall goal of this Program Project is to improve the outcome of autologous marrow transplantation (AMT) in the treatment of hematologic malignancies. General topics which will be addressed by this Program Project include the eradication of malignancy, the clonality of hematopoiesis, the effects of peripheral blood progenitors on engraftment, effects of growth factors and attempts to block in vivo growth inhibitors. Seven individual research projects are proposed which will work collaboratively on these topics: 1.Evaluation of AMT. a.Acute lymphoblastic leukemia and malignant lymphoma. b.Acute myeloid leukemia. 2.Contribution of genetically marked peripheral blood repopulating cells to hematopoietic reconstitution after AMT. 3.Hematopoietic growth factors: preclinical evaluation. 4.Colony Forming Cells: generation from precursors in Acute Myeloid Leukemia. 5.Clonal hematopoiesis: an evaluation of clonal origins in malignancy and hematopoiesis. 6.Growth factors in autologous marrow transplant. 7.Evaluation of Lymphokines and Adoptive immunotherapy following AMT. Our ability to carry out the studies proposed in this Program Project is enhanced by: 1) preclinical research programs which focus on murine, canine, or non-human primate models and allow rapid and logical translation of preclinical concepts to clinical trials, 2) the accrual of over 120 autologous transplant patients onto research studies each year, 3) supportive care programs in biostatistics, marrow processing, outpatient and long-term follow-up, pathology, infectious disease consulting, pharmacology, nutrition services, transfusion support and administration, and 4) a unique structure as a large group of investigators all of whom are focused on the general topic of marrow transplantation. Success in achieving the goals of this Program Project will have relevance for the use of other intensive therapies to treat hematologic malignancies, for the wider application of AMT in the treatment of other malignant and nonmalignant diseases, and for the care of pancytopenic and immunocompromised patients.